In a prospective case study of 71 eyes of 71 patients whose treatment was switched to faricimab from other anti-vascular endothelial growth factors (VEGF) agents for neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), one patient showed IOI in the form of mild vitritis without vasculitis [7]. This evidence concerns the gene VEGFA and vasculitis.